Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ARQT | US
-0.21
-2.05%
Healthcare
Biotechnology
30/06/2024
04/10/2024
10.02
10.20
10.44
9.83
Arcutis Biotherapeutics Inc. a biopharmaceutical company focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151 a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154 a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252 a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255 a topical formulation of ivarmacitinib designed to reach deeper into the skin in order to treat alopecia areata; and ARQ-234 a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis Inc. and changed its name to Arcutis Biotherapeutics Inc. in October 2019. Arcutis Biotherapeutics Inc. was incorporated in 2016 and is headquartered in Westlake Village California.
View LessStrong Revenue Growth (> 10%)
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Weak Operating Margin (< 10%)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
60.4%1 month
51.7%3 months
71.0%6 months
74.9%-
-
5.74
1.11
0.47
-2.04
6.93
-
-178.29M
1.17B
1.17B
-
-162.28
-
494.60
-148.92
11.30
26.32
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
1.42
Range1M
2.17
Range3M
3.47
Rel. volume
0.84
Price X volume
16.26M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Avadel Pharmaceuticals plc | AVDL | Biotechnology | 13.09 | 1.26B | 0.23% | n/a | 53.59% |
Mesoblast Limited | MESO | Biotechnology | 10.81 | 1.26B | 23.40% | n/a | 24.76% |
Wave Life Sciences Ltd | WVE | Biotechnology | 8.41 | 1.24B | -4.76% | n/a | 656.70% |
Innoviva Inc | INVA | Biotechnology | 19.67 | 1.23B | 0.56% | 10.92 | 67.72% |
ANI Pharmaceuticals Inc | ANIP | Biotechnology | 57.83 | 1.22B | 0.57% | 49.40 | 68.04% |
Fluent Inc | COGT | Biotechnology | 11.11 | 1.22B | 3.64% | n/a | 4.87% |
PHATHOM PHARMACEUTICALS INC. | PHAT | Biotechnology | 17.25 | 1.20B | 2.92% | n/a | -216.56% |
Travere Therapeutics Inc. | TVTX | Biotechnology | 15.23 | 1.16B | 9.81% | n/a | 2662.08% |
Tyra Biosciences Inc. Common Stock | TYRA | Biotechnology | 22.04 | 1.16B | -1.52% | n/a | 1.70% |
Praxis Precision Medicines Inc | PRAX | Biotechnology | 64.94 | 1.15B | 6.22% | n/a | 0.46% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Pitney Bowes Inc | PBI | Building Products & Equipment | 6.92 | 1.24B | 1.91% | n/a | -571.93% |
ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 11.47 | 1.15B | 0.09% | n/a | 19.46% |
Camping World Holdings Inc | CWH | Recreational Vehicles | 23.44 | 1.06B | -0.38% | n/a | 3644.76% |
Malibu Boats Inc | MBUU | Recreational Vehicles | 39.7 | 793.63M | -0.68% | n/a | 1.50% |
Latham Group Inc. | SWIM | Building Products & Equipment | 6.64 | 767.43M | 0.00% | 61.27 | 77.00% |
Ennis Inc | EBF | Building Products & Equipment | 24.31 | 631.67M | 2.36% | 15.15 | 2.42% |
ACCO Brands Corporation | ACCO | Building Products & Equipment | 5.25 | 502.94M | -0.19% | n/a | 174.23% |
Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 11.63 | 366.05M | 0.00% | 47.92 | 88.92% |
ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 21.28 | 334.47M | -4.23% | n/a | 286.96% |
Marine Products Corporation | MPX | Recreational Vehicles | 9.47 | 328.78M | 0.21% | 13.24 | 0.00% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -2.04 | 0.76 | Cheaper |
Ent. to Revenue | 6.93 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 5.74 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 71.02 | 74.67 | Par |
Debt to Equity | 1.11 | -1.82 | Expensive |
Debt to Assets | 0.47 | 0.26 | Expensive |
Market Cap | 1.17B | 3.73B | Emerging |